Dr. Lal PathLabs has declared a final dividend of ₹4 per equity share, equivalent to 40% on a face value of ₹10 each, for the financial year ending 31 March 2026. This dividend is subject to approval by the company’s members at the upcoming Annual General Meeting (AGM), with the record date set for 26 June 2026. The dividend will be credited within 30 days following member approval.
In a strategic move, Dr. Lal PathLabs has acquired a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly-owned subsidiary. This acquisition aligns with the company’s expansion strategy, although specific financial details of the transaction were not disclosed.
The company is also expanding its international footprint with the incorporation of a wholly-owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO. This development is pending necessary regulatory and statutory approvals.
Additionally, the board has approved the re-appointment of (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for a five-year term starting 1 April 2027. Mr. Rajit Mehta has also been re-appointed as a Non-Executive Independent Director for a five-year term commencing 27 July 2026. Both appointments are subject to member approval at the AGM.
The company has designated Dr. Reena Nakra as Chief Scientific Officer and Dr. Saloni Khera as Chief Lab Management Officer, both as Senior Management Personnel effective 30 April 2026.
Dr. Lal PathLabs has re-appointed M/s Ernst & Young LLP as the Internal Auditors and M/s A.G. Agarwal & Associates as the Cost Auditors for the financial year 2026-27.
Furthermore, 82,750 equity shares have been allotted under the Employee Stock Option Plan 2022, increasing the paid-up equity share capital to ₹1,67,63,77,700, divided into 16,76,37,770 equity shares of ₹10 each.
The 32nd Annual General Meeting of the company is scheduled for 25 July 2026, to be conducted via video conferencing or other audio-visual means.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).